This afternoon we watched Series drop -1.3% to a price of $73.39 per share. The Large-Cap Medical Instruments & Supplies company is now trading -15.65% below its average target price of $87.0. Analysts have set target prices ranging from $73.0 to $103.0 per share for Series, and have given the stock an average rating of hold.
The stock has an average amount of shares sold short at 2.7%, and a short ratio of 5.91. The company's insiders own 19.96% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 68.2% of Series's shares being owned by this investor type.
Institutions Invested in Series
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-06-30 | Vanguard Group Inc | 9% | 16,253,361 | $1,192,752,931 |
| 2025-06-30 | Independent Franchise Partners, LLP | 6% | 10,141,066 | $744,202,150 |
| 2025-06-30 | Blackrock Inc. | 6% | 9,646,550 | $707,912,092 |
| 2025-03-31 | Trian Fund Management, LP | 5% | 8,462,819 | $621,043,990 |
| 2025-03-31 | State Street Corporation | 4% | 6,199,316 | $454,936,817 |
| 2025-06-30 | Davis Selected Advisers, LP | 3% | 5,492,661 | $403,078,939 |
| 2025-06-30 | Boston Partners | 2% | 3,670,757 | $269,378,510 |
| 2025-06-30 | Geode Capital Management, LLC | 2% | 3,563,792 | $261,528,883 |
| 2025-03-31 | Madison Avenue Partners, LP | 2% | 2,813,017 | $206,433,258 |
| 2025-06-30 | Invesco Ltd. | 2% | 2,665,259 | $195,590,037 |
Besides an analyst consensus of some upside potential, other market factors point to there being mixed market sentiment on Series.
